Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data-Reference-Cited by-同舟云学术

Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data

Published:2015-01-14 Issue:5 Volume:16 Page:297-306
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Med

Author:

Vingerhoets J¹,Calvez V²,Flandre P²,Marcelin A-G²,Ceccherini-Silberstein F³,Perno C-F³,Mercedes Santoro M³,Bateson R⁴,Nelson M⁴,Cozzi-Lepri A⁵,Grarup J⁵,Lundgren J⁵,Incardona F⁶,Kaiser R⁷,Sonnerborg A⁸,Clotet B⁹,Paredes R⁹,Günthard HF¹⁰,Ledergerber B¹⁰,Hoogstoel A¹,Nijs S¹,Tambuyzer L¹,Lavreys L¹,Opsomer M¹,

Affiliation:

1. Janssen Infectious Diseases BVBA; Beerse Belgium

2. ANRS/INSERM; UPMC University of Paris 06; UMR_S 1136; The Pierre Louis Institute of Epidemiology and Public Health; F-75013; University of Sorbonne; Paris France

3. Tor Vergata University; Rome Italy

4. St Stephen's Centre; Chelsea & Westminster Hospital; London UK

5. EuroSIDA; Copenhagen Denmark

6. Informa s.r.l.; EuResist Network GEIE; Rome Italy

7. Institute of Virology; EUResist Network GEIE; University of Cologne; Cologne Germany

8. Karolinska Institute; EUResist Network GEIE; Stockholm Sweden

9. Fight Against AIDS Foundation; Barcelona Spain

10. Swiss HIV Cohort Study; Division of Infectious Diseases and Hospital Epidemiology; University Hospital Zürich; University of Zürich; Zürich Switzerland

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Reference18 articles.

1. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1;Andries;Antimicrob Agents Chemother,2004

2. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments;Vingerhoets;J Virol,2005

3. INTELENCE ® (etravirine) summary of product characteristics 2008 http://www.medicines.org.uk/emc/medicine/21185/SPC/Intelence+100+mg+tablets

4. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial;Lazzarin;Lancet,2007

5. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial;Madruga;Lancet,2007

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cohort Profile: A European Multidisciplinary Network for the Fight against HIV Drug Resistance (EuResist Network);Tropical Medicine and Infectious Disease;2023-04-23

2. Extractive determination study of Etravirine by using Tpooo as an Analytical reagent in Pure and Pharmaceutical dosage forms;Research Journal of Pharmacy and Technology;2022-03-24

3. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study;The Lancet HIV;2019-09

4. The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro;Journal of Antimicrobial Chemotherapy;2018-11-20

5. Impact of etravirine on hospitalization rate between 2005 and 2011 among heavily treated HIV-1-infected individuals on failing regimens;BMC Infectious Diseases;2018-07-11